BIOPHYTIS is a biotechnology company created in 2006, specialising in diseases associated with aging, particularly those affecting muscular and visual functions.
Aging science
By understanding the relationship between natural active substances and degeneration processes BIOPHYTIS is able to identify families of substances capable of acting directly on the mechanism of the disease.
BIOPHYTIS has a portfolio of first-in-class drug candidates, at various stages of development, for treating certain indications of sarcopenia and AMD, for which there is currently no treatment.
17 October 2017

Biophytis will present at the Galien MedStartUp Partnering Day on October 26, 2017 in New York

11 October 2017

Biophytis completes a €10.4 M capital increase to finance mid-stage clinical trials for two novel anti-aging drug-candidates. Read the Press Release